Worth Watching Stocks Watch List: Keryx Biopharmaceuticals (NASDAQ:KERX), Liberty Interactive Group (NASDAQ:QVCA)

On Thursday, Shares of Keryx Biopharmaceuticals (NASDAQ:KERX), added 3.50% and closed at $5.62 in the last trading session. The last trading range of the stock ranges between $5.36 and $5.72. Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, recently declared that the U.S. Food and Drug Administration (FDA) has approved its application for a second drug product contract manufacturer. Patheon Manufacturing Services LLC of Greenville, North Carolina, a leading global provider of pharmaceutical manufacturing services, is now an FDA approved drug product manufacturer of Auryxia®. With FDA approval of this manufacturer, the company has rebuilt supply and will promptly make Auryxia available to wholesalers.

“We are happy with recently’s approval, as it expands our manufacturing capabilities and capacity,” said Greg Madison, president and chief executive officer of Keryx Biopharmaceuticals. “Getting a second drug product manufacturer approved was an important step to ensuring long-term supply of Auryxia is consistently available to patients.”

Liberty Interactive Group (NASDAQ:QVCA), dropped -1.28% and closed at $19.99 in the last trading session. The last trading range of the stock ranges between $19.96 and $20.99. The company’s Market capitalization is $13.36 Billion with the total Outstanding Shares of 466.95 million. Liberty Interactive Corporation (“Liberty Interactive”) (Nasdaq: QVCA, QVCB, LVNTA, LVNTB) recently stated third quarter 2016 results. Highlights include(1):

Attributed to QVC Group

QVC merged revenue down 3% to $1.9 billion

Local currency sales gains in all merged international markets

QVC merged mobile penetration was 59% of QVC.com orders, a 603 basis point increase

QVC US mobile penetration was 58% of QVC.com orders, a 578 basis point increase

QVC US mobile penetration was 58% of QVC.com orders, a 578 basis point increase

zulily revenue grew 14% to $359 million and operating loss was $52 million, mainly as a result of about $60 million of amortization of intangible assets recognized in purchase accounting

Leave a Reply

Your email address will not be published. Required fields are marked *